BR112014026957A8 - micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior - Google Patents
micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superiorInfo
- Publication number
- BR112014026957A8 BR112014026957A8 BR112014026957A BR112014026957A BR112014026957A8 BR 112014026957 A8 BR112014026957 A8 BR 112014026957A8 BR 112014026957 A BR112014026957 A BR 112014026957A BR 112014026957 A BR112014026957 A BR 112014026957A BR 112014026957 A8 BR112014026957 A8 BR 112014026957A8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- respiratory tract
- treatment
- delivery system
- upper respiratory
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010057190 Respiratory tract infections Diseases 0.000 title abstract 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 title abstract 2
- 239000011859 microparticle Substances 0.000 title abstract 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 abstract 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166595 | 2012-05-03 | ||
| PCT/EP2013/059079 WO2013164380A1 (en) | 2012-05-03 | 2013-05-02 | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014026957A2 BR112014026957A2 (pt) | 2017-06-27 |
| BR112014026957A8 true BR112014026957A8 (pt) | 2018-01-16 |
Family
ID=48430695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014026957A BR112014026957A8 (pt) | 2012-05-03 | 2013-05-02 | micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9682096B2 (https=) |
| EP (1) | EP2846767B1 (https=) |
| JP (1) | JP6349304B2 (https=) |
| KR (1) | KR102240042B1 (https=) |
| CN (1) | CN104394846B (https=) |
| AU (1) | AU2013255885C1 (https=) |
| BR (1) | BR112014026957A8 (https=) |
| CA (1) | CA2866230C (https=) |
| CL (1) | CL2014002929A1 (https=) |
| CO (1) | CO7101247A2 (https=) |
| ES (1) | ES2911116T3 (https=) |
| IN (1) | IN2014MN02359A (https=) |
| MX (1) | MX2014013256A (https=) |
| NZ (1) | NZ630040A (https=) |
| RU (1) | RU2650636C2 (https=) |
| SG (2) | SG11201406208QA (https=) |
| WO (1) | WO2013164380A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630040A (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| KR20160072140A (ko) * | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
| GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| MA44384A (fr) * | 2015-05-11 | 2019-01-23 | Janssen Sciences Ireland Unlimited Co | Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures |
| HUE047172T2 (hu) | 2015-11-17 | 2020-04-28 | Bioncotech Therapeutics S L | Újfajta gyógyszerészeti készítmény, mely egy kétszálú poli-ribonukleotid és egy polialkilén-imin egy komplexét tartalmazó részecskéket tartalmaz |
| MX2018006575A (es) * | 2015-11-30 | 2018-12-06 | Novus Therapeutics Inc | Composiciones y metodos para profilaxis otologica y tratamiento. |
| CN110177545A (zh) | 2016-11-16 | 2019-08-27 | 爱尔兰詹森科学公司 | 用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂 |
| ES2924138T3 (es) | 2017-05-17 | 2022-10-04 | Highlight Therapeutics S L | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
| WO2020001587A1 (zh) | 2018-06-29 | 2020-01-02 | 信福(北京)医药科技有限公司 | 用于增强免疫响应的复合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| ATE154241T1 (de) | 1991-10-01 | 1997-06-15 | Takeda Chemical Industries Ltd | Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| CA2203843C (en) * | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| JP2004510724A (ja) * | 2000-10-06 | 2004-04-08 | ヤゴテック アーゲー | 分子量の低下した澱粉からなる微粒子中に埋め込まれた免疫学的活性物質を含むワクチン組成物 |
| WO2004041183A2 (en) * | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| RU2390351C2 (ru) | 2003-08-11 | 2010-05-27 | Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити | Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа |
| US20050244505A1 (en) * | 2003-12-11 | 2005-11-03 | Higbee Russell G | Immunotherapy compositions, method of making and method of use thereof |
| CN101229378A (zh) | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
| AU2005332599B2 (en) | 2005-06-08 | 2012-02-16 | Yisheng Biopharma (Singapore) Pte. Ltd. | Polyinosinic acid-polycytidylic acid-based adjuvant |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| US7999119B2 (en) | 2006-07-22 | 2011-08-16 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
| JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
| UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
| EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
| CN102281870B (zh) * | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| CN101491503A (zh) | 2008-12-17 | 2009-07-29 | 天津瑞普生物技术股份有限公司 | 一种用于宠物的聚肌胞滴丸及其制备方法 |
| WO2010073247A2 (en) | 2008-12-22 | 2010-07-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Egfr-homing double-stranded rna vector for systemic cancer treatment |
| CN101757018A (zh) * | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
| ES2588183T3 (es) | 2009-03-31 | 2016-10-31 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal |
| EP2598145A1 (en) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| NZ630040A (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| KR20160072140A (ko) | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
-
2013
- 2013-05-02 NZ NZ630040A patent/NZ630040A/en not_active IP Right Cessation
- 2013-05-02 IN IN2359MUN2014 patent/IN2014MN02359A/en unknown
- 2013-05-02 MX MX2014013256A patent/MX2014013256A/es unknown
- 2013-05-02 AU AU2013255885A patent/AU2013255885C1/en not_active Ceased
- 2013-05-02 SG SG11201406208QA patent/SG11201406208QA/en unknown
- 2013-05-02 EP EP13722334.3A patent/EP2846767B1/en active Active
- 2013-05-02 BR BR112014026957A patent/BR112014026957A8/pt not_active Application Discontinuation
- 2013-05-02 WO PCT/EP2013/059079 patent/WO2013164380A1/en not_active Ceased
- 2013-05-02 ES ES13722334T patent/ES2911116T3/es active Active
- 2013-05-02 SG SG10201607288VA patent/SG10201607288VA/en unknown
- 2013-05-02 US US14/398,573 patent/US9682096B2/en not_active Expired - Fee Related
- 2013-05-02 RU RU2014148544A patent/RU2650636C2/ru active
- 2013-05-02 JP JP2015509432A patent/JP6349304B2/ja not_active Expired - Fee Related
- 2013-05-02 CN CN201380023084.4A patent/CN104394846B/zh not_active Expired - Fee Related
- 2013-05-02 KR KR1020147028656A patent/KR102240042B1/ko not_active Expired - Fee Related
- 2013-05-02 CA CA2866230A patent/CA2866230C/en active Active
-
2014
- 2014-10-15 CO CO14228077A patent/CO7101247A2/es unknown
- 2014-10-29 CL CL2014002929A patent/CL2014002929A1/es unknown
-
2016
- 2016-06-13 US US15/180,603 patent/US9987300B2/en active Active
-
2018
- 2018-05-07 US US15/972,840 patent/US10485816B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160296551A1 (en) | 2016-10-13 |
| IN2014MN02359A (https=) | 2015-08-14 |
| EP2846767B1 (en) | 2022-01-26 |
| RU2014148544A (ru) | 2016-06-27 |
| US9987300B2 (en) | 2018-06-05 |
| AU2013255885C1 (en) | 2018-04-26 |
| US20180325939A1 (en) | 2018-11-15 |
| NZ630040A (en) | 2016-10-28 |
| US9682096B2 (en) | 2017-06-20 |
| KR102240042B1 (ko) | 2021-04-14 |
| RU2650636C2 (ru) | 2018-04-16 |
| CN104394846A (zh) | 2015-03-04 |
| AU2013255885B2 (en) | 2017-10-05 |
| ES2911116T3 (es) | 2022-05-17 |
| CA2866230A1 (en) | 2013-11-07 |
| CN104394846B (zh) | 2018-10-19 |
| US20150140042A1 (en) | 2015-05-21 |
| BR112014026957A2 (pt) | 2017-06-27 |
| CL2014002929A1 (es) | 2015-01-16 |
| SG11201406208QA (en) | 2014-11-27 |
| HK1203390A1 (en) | 2015-10-30 |
| EP2846767A1 (en) | 2015-03-18 |
| AU2013255885A1 (en) | 2014-09-25 |
| CA2866230C (en) | 2020-08-18 |
| SG10201607288VA (en) | 2016-10-28 |
| KR20150008855A (ko) | 2015-01-23 |
| WO2013164380A1 (en) | 2013-11-07 |
| US10485816B2 (en) | 2019-11-26 |
| JP2015515968A (ja) | 2015-06-04 |
| CO7101247A2 (es) | 2014-10-31 |
| MX2014013256A (es) | 2015-01-16 |
| JP6349304B2 (ja) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014026957A8 (pt) | micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior | |
| ES2731899T3 (es) | Composición de vacuna nasal contra la gripe | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112013029537A2 (pt) | derivados de quinazolina para tratamento de infecções virais e outras doenças | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| BR112015003590A8 (pt) | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112014009238A8 (pt) | compostos de (hetero)aril ciclopropilamina, seus usos e seu processo de preparação, e composições farmacêuticas | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| BR112015022623A2 (pt) | composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| MX2016005883A (es) | Formulaciones de acido poliinosinico-policitidilico (poli (i:c))para el tratamiento de infecciones del tracto respiratorio superior. | |
| JP2010285436A5 (https=) | ||
| JP2022180360A (ja) | ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用 | |
| BRPI0517374A (pt) | formulação para tratamento ou prevenção de infecção respiratória, método para tratamento | |
| JP2014510130A5 (https=) | ||
| WO2010138419A3 (en) | Materials and methods for treating viral infections | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| BR112014027213A2 (pt) | nova composição de alfentanil para o tratamento da dor aguda | |
| BR112012023396A2 (pt) | Micelas de gangliosídeo como um sistema de entrega para drogas hidrofóbicas | |
| BR112015013215A2 (pt) | proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |